Cargando…
The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy
PURPOSE: To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting early treatment response. MATERIALS AND METHODS: Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) were enrolled. Pelvic DCE-MRI scans we...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349537/ https://www.ncbi.nlm.nih.gov/pubmed/34377025 http://dx.doi.org/10.2147/CMAR.S314289 |
_version_ | 1783735583844073472 |
---|---|
author | Lu, Heming Wu, Yuying Liu, Xu Huang, Huixian Jiang, Hailan Zhu, Chaohua Man, Yuping Liu, Pei Li, Xianglong Chen, Zhaohong Long, Xianfeng Pang, Qiang Deng, Shan Gu, Junzhao |
author_facet | Lu, Heming Wu, Yuying Liu, Xu Huang, Huixian Jiang, Hailan Zhu, Chaohua Man, Yuping Liu, Pei Li, Xianglong Chen, Zhaohong Long, Xianfeng Pang, Qiang Deng, Shan Gu, Junzhao |
author_sort | Lu, Heming |
collection | PubMed |
description | PURPOSE: To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting early treatment response. MATERIALS AND METHODS: Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) were enrolled. Pelvic DCE-MRI scans were performed before RT (pre-RT), in the middle of RT (mid-RT), and at the end of RT (post-RT), separately. Parameters (ie, K(trans), K(ep), and V(e)) were measured. Pre-, mid-, and post-RT K(trans) were denoted as K(trans)-preTx, K(trans)-midTx, and K(trans)-postTx, respectively. And the same denoting rule also went for K(ep) and V(e). Difference for the same parameter such as K(trans) measured between two consecutive time points was calculated as second K(trans) value minus first K(trans) value. The differences in K(trans) between pre-RT and post-RT, between pre-RT and mid-RT, and between mid-RT and post-RT were denoted as ΔK(trans)-post-preTx, ΔK(trans)-mid-preTx, and ΔK(trans)-post-midTx, respectively, and the same denoting rule was also applied to K(ep) and V(e). RESULTS: A total of 57 patients were enrolled. After the treatment, 31 patients had complete response (CR group). The remaining 26 patients had partial response (NCR group). Significant differences were found in K(trans)-postTx, K(ep-)postTx, V(e-)midTx, ΔK(trans)-post-preTx, ΔK(trans)-post-midTx, ΔK(ep-)post-preTx, ΔK(ep-)mid-preTx and ΔK(ep-)post-midTx between the two groups. Receiver operating characteristic (ROC) analysis for their performances in predicting treatment response showed an area under curve (AUC) of 0.656–0.849, sensitivity of 61.3–93.5%, specificity of 46.1–73.1%, and maximal Youden Index of 36.5–66.6. Among those parameters, K(ep-)postTx was the best, and its AUC, sensitivity, specificity, maximal Youden Index, and cutoff value were 0.849, 87.1%, 73.1%, 60.2, and 0.341, respectively. These combined parameters showed an AUC of 0.952, with sensitivity of 87.1%, specificity of 96.1%, and maximal Youden Index of 83.2. CONCLUSION: DCE-MRI parameters can predict early treatment outcome. Among those parameters, K(ep-)postTx is the best predictor. The combination of multi-parameters can increase the predictive potency. |
format | Online Article Text |
id | pubmed-8349537 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-83495372021-08-09 The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy Lu, Heming Wu, Yuying Liu, Xu Huang, Huixian Jiang, Hailan Zhu, Chaohua Man, Yuping Liu, Pei Li, Xianglong Chen, Zhaohong Long, Xianfeng Pang, Qiang Deng, Shan Gu, Junzhao Cancer Manag Res Original Research PURPOSE: To evaluate the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in predicting early treatment response. MATERIALS AND METHODS: Patients with locally advanced cervical cancer (LACC) treated with concurrent chemoradiotherapy (CCRT) were enrolled. Pelvic DCE-MRI scans were performed before RT (pre-RT), in the middle of RT (mid-RT), and at the end of RT (post-RT), separately. Parameters (ie, K(trans), K(ep), and V(e)) were measured. Pre-, mid-, and post-RT K(trans) were denoted as K(trans)-preTx, K(trans)-midTx, and K(trans)-postTx, respectively. And the same denoting rule also went for K(ep) and V(e). Difference for the same parameter such as K(trans) measured between two consecutive time points was calculated as second K(trans) value minus first K(trans) value. The differences in K(trans) between pre-RT and post-RT, between pre-RT and mid-RT, and between mid-RT and post-RT were denoted as ΔK(trans)-post-preTx, ΔK(trans)-mid-preTx, and ΔK(trans)-post-midTx, respectively, and the same denoting rule was also applied to K(ep) and V(e). RESULTS: A total of 57 patients were enrolled. After the treatment, 31 patients had complete response (CR group). The remaining 26 patients had partial response (NCR group). Significant differences were found in K(trans)-postTx, K(ep-)postTx, V(e-)midTx, ΔK(trans)-post-preTx, ΔK(trans)-post-midTx, ΔK(ep-)post-preTx, ΔK(ep-)mid-preTx and ΔK(ep-)post-midTx between the two groups. Receiver operating characteristic (ROC) analysis for their performances in predicting treatment response showed an area under curve (AUC) of 0.656–0.849, sensitivity of 61.3–93.5%, specificity of 46.1–73.1%, and maximal Youden Index of 36.5–66.6. Among those parameters, K(ep-)postTx was the best, and its AUC, sensitivity, specificity, maximal Youden Index, and cutoff value were 0.849, 87.1%, 73.1%, 60.2, and 0.341, respectively. These combined parameters showed an AUC of 0.952, with sensitivity of 87.1%, specificity of 96.1%, and maximal Youden Index of 83.2. CONCLUSION: DCE-MRI parameters can predict early treatment outcome. Among those parameters, K(ep-)postTx is the best predictor. The combination of multi-parameters can increase the predictive potency. Dove 2021-08-04 /pmc/articles/PMC8349537/ /pubmed/34377025 http://dx.doi.org/10.2147/CMAR.S314289 Text en © 2021 Lu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Lu, Heming Wu, Yuying Liu, Xu Huang, Huixian Jiang, Hailan Zhu, Chaohua Man, Yuping Liu, Pei Li, Xianglong Chen, Zhaohong Long, Xianfeng Pang, Qiang Deng, Shan Gu, Junzhao The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy |
title | The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy |
title_full | The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy |
title_fullStr | The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy |
title_full_unstemmed | The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy |
title_short | The Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Treatment Response for Cervical Cancer Treated with Concurrent Chemoradiotherapy |
title_sort | role of dynamic contrast-enhanced magnetic resonance imaging in predicting treatment response for cervical cancer treated with concurrent chemoradiotherapy |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349537/ https://www.ncbi.nlm.nih.gov/pubmed/34377025 http://dx.doi.org/10.2147/CMAR.S314289 |
work_keys_str_mv | AT luheming theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT wuyuying theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT liuxu theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT huanghuixian theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT jianghailan theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT zhuchaohua theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT manyuping theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT liupei theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT lixianglong theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT chenzhaohong theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT longxianfeng theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT pangqiang theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT dengshan theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT gujunzhao theroleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT luheming roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT wuyuying roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT liuxu roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT huanghuixian roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT jianghailan roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT zhuchaohua roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT manyuping roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT liupei roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT lixianglong roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT chenzhaohong roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT longxianfeng roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT pangqiang roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT dengshan roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy AT gujunzhao roleofdynamiccontrastenhancedmagneticresonanceimaginginpredictingtreatmentresponseforcervicalcancertreatedwithconcurrentchemoradiotherapy |